Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck's Backbone Is Cardiovascular, Infectious Disease After Pipeline Integration

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck's late-stage pipeline includes more than 40 compounds in Phase II and Phase III development after combining with Schering-Plough's assets.

You may also be interested in...



Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.

Merck Infectious Disease Head Touts Diversity Of Post-Schering Merger Anti-Infective Portfolio

BOSTON – Merck & Co.'s purchase of Schering-Plough created probably the most broad and comprehensive pipeline of anti-infective agents in the industry, according to Roger Pomerantz, Merck's senior vice president and global franchise head, infectious diseases.

Merck Cuts 8 Research, 8 Manufacturing Sites As Part Of Schering Integration

With Schering-Plough integration under way, Merck will phase out research and manufacturing operations in effort to achieve $3.5 billion in savings by 2012.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS070322

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel